Concordance of Post-consolidation Minimal Residual Disease Rates by Multiparametric Flow Cytometry and Next-generation Sequencing in CASSIOPEIA

被引：16

作者：

Avet-Loiseau, Herve ^{[1
]}

Bene, Marie C. ^{[2
]}

Wuilleme, Soraya ^{[2
]}

Corre, Jill ^{[1
]}

Attal, Michel ^{[3
]}

Arnulf, Bertrand ^{[4
]}

Garderet, Laurent ^{[5
]}

Macro, Margaret ^{[6
]}

Stoppa, Anne-Marie ^{[7
]}

Delforge, Michel ^{[8
]}

Broijl, Annemiek ^{[9
]}

Zweegman, Sonja ^{[10
]}

Jie, Kon-Siong ^{[11
]}

Van de Donk, Niels ^{[12
]}

Pei, Lixia ^{[13
]}

de Boer, Carla ^{[14
]}

Chiu, Chris ^{[15
]}

Vanquickelberghe, Veronique ^{[16
]}

Kampfenkel, Tobias ^{[14
]}

Vermeulen, Jessica ^{[14
]}

Moreau, Philippe ^{[17
]}

Sonneveld, Pieter ^{[9
]}

机构：

[1] IUC T Oncopole, Unite Genom Myelome, Toulouse, France

[2] Univ Hosp Hotel Dieu, Hematol Biol, Nantes, France

[3] Inst Univ Canc Toulouse Oncopole, Toulouse, France

[4] Hop St Louis, Hematol Oncol, Paris, France

[5] Sorbonne Univ, INSERM, Paris, France

[6] CHU Caen, Caen, France

[7] Inst Paoli Calmettes, Marseille 9, France

[8] Univ Ziekenhuizen Leuven, Leuven, Belgium

[9] Erasmus MC Canc Inst, Rotterdam, Netherlands

[10] Vrije Univ Amsterdam, Amsterdam UMC, Dept Hematol, Amsterdam, Netherlands

[11] Zuyderland MC, Sittard, Netherlands

[12] Vrije Univ Amsterdam Med Ctr, Dept Hematol, Amsterdam, Netherlands

[13] Janssen Res & Dev LLC, Raritan, NJ USA

[14] Janssen Res & Dev LLC, Leiden, Netherlands

[15] Janssen Res & Dev LLC, Spring House, PA USA

[16] Janssen Res & Dev, Beerse, Belgium

[17] Univ Hosp Hotel Dieu, Hematol, Nantes, France

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期

关键词：

daratumumab; Multiple myeloma; transplant;

D O I：

10.1016/j.clml.2019.09.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OAB-004

引用

页码：E3 / E4

页数：2

共 50 条

[31] The role of multiparametric flow cytometry in the detection of minimal residual disease in acute leukaemia
Lee, Denise
Grigoriadis, George
Westerman, David
PATHOLOGY, 2015, 47 (07) : 609 - 621
[32] Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing Feasibility, Challenges, and Direct Comparison with High-Sensitivity Flow Cytometry
Ho, Caleb
Syed, Mustafa
Roshal, Mikhail
Petrova-Drus, Kseniya
Moung, Christine
Yao, Jinjuan
Quesada, Andres E.
Benhamida, Jamal
Vanderbilt, Chad
Liu, Ying
Zhu, Menglei
Yu, Wayne
Maciag, Lidia
Wang, Meiyi
Ma, Yuanyuan
Gao, Qi
Rustad, Even H.
Hultcrantz, Malin
Diamond, Benjamin T.
Zheng-Lin, Binbin
Huang, Ying
Hutt, Kasey
Miller, Jeffrey E.
Dogan, Ahmet
Nafa, Khedoudja
Landgren, Ola
Arcila, Maria E.
JOURNAL OF MOLECULAR DIAGNOSTICS, 2021, 23 (02): : 181 - 199
[33] Comparison of next-generation sequencing and flow cytometry in detecting minimal residual disease in adult acute lymphoid leukemia: Evaluating clinical outcomes in a single-center study
Nittur, Vinay
Ashouri, Karam
Adnani, Blake
Hwang, Jennifer
Chen, Denaly
Schiff, Kimberly
Savitala-Damerla, Lakshmi
Ladha, Abdullah
Woan, Karrune
Tam, Eric Leon
Chaudhary, Preet
Yaghmour, George
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[34] Minimal Residual Disease Evaluation By Multiparameter Flow Cytometry and Next Generation Sequencing in the Forte Trial for Newly Diagnosed Multiple Myeloma Patients
Oliva, Stefania
Genuardi, Elisa
Belotti, Angelo
Frascione, Pio Manlio Mirko
Galli, Monica
Capra, Andrea
Offidani, Massimo
Vozella, Federico
Zambello, Renato
Auclair, Daniel
Siniscalchi, Agostina
Yesil, Jennifer
Annibali, Ombretta
Kirsch, Ilan M.
Caltagirone, Simona
Jacob, Allison P.
Ballanti, Stelvio
Palmas, Angelo D.
Ledda, Antonio
Corradini, Paolo
Omede, Paola
Cavo, Michele
Musto, Pellegrino
Boccadoro, Mario
Gay, Francesca
BLOOD, 2019, 134
[35] Integrating Next Generation Flow Cytometry and Next-Generation Sequencing for an Enhanced Detection of Measurable Residual Disease in Acute Myeloid Leukemia with Myelodysplasia-Related Gene Mutations
Pinero, Paula
Gonzalez, Rocio
Marin, Elena
Gonzalez, Marina
Diaz, Vanesa
Lopez, Javier
Manresa, Pablo
Tarin, Fabian
BLOOD, 2024, 144 : 6165 - 6166
[36] Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy
Thompson, Philip A.
Srivastava, Jaya
Peterson, Christine
Strati, Paolo
Jorgensen, Jeffrey L.
Hether, Tyler
Keating, Michael J.
O'Brien, Susan M.
Ferrajoli, Alessandra
Burger, Jan A.
Estrov, Zeev
Jain, Nitin
Wierda, William G.
BLOOD, 2019, 134 (22) : 1951 - 1959
[37] Minimal residual disease assessment by next-generation sequencing. Better tools to gaze into the crystal ball?
Balduzzi, A.
BONE MARROW TRANSPLANTATION, 2017, 52 (07) : 952 - 954
[38] Next-Generation Sequencing and Detection of Minimal Residual Disease in Acute Myeloid Leukemia Ready for Clinical Practice?
Pastore, Friederike
Levine, Ross L.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (08): : 778 - 780
[39] Next-Generation Sequencing of FLT3/ITD for Minimal Residual Disease Monitoring in Leukemia Patients
Xie, Z.
Carson, A. R.
McClain, V.
Zheng, S.
Huang, W.
Miller, J. E.
Levis, M.
Stenzel, T.
JOURNAL OF MOLECULAR DIAGNOSTICS, 2016, 18 (06): : 967 - 967
[40] Minimal residual disease assessment by next-generation sequencing. Better tools to gaze into the crystal ball?
A Balduzzi
Bone Marrow Transplantation, 2017, 52 : 952 - 954

← 1 2 3 4 5 →